Comparative Pharmacology
Head-to-head clinical analysis: GENERLAC versus PLEGISOL IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENERLAC versus PLEGISOL IN PLASTIC CONTAINER.
GENERLAC vs PLEGISOL IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is metabolized by colonic bacteria to short-chain fatty acids (e.g., lactic, acetic, and formic acids), which osmotically increase intraluminal water content, soften stool, and stimulate peristalsis. In hepatic encephalopathy, the acidic environment reduces intestinal ammonia production and absorption by promoting conversion of NH3 to NH4+.
PLEGISOL is an extracellular-type crystalloid cardioplegic solution used for myocardial protection during cardiac surgery. Its mechanism involves inducing rapid cardiac arrest by high potassium concentration (depolarizing arrest), reducing myocardial oxygen demand, and providing buffering capacity via tromethamine to maintain pH. The solution also contains magnesium to stabilize membranes and mannitol as an osmotic agent to reduce edema.
10-45 mL orally once daily, adjusted to produce 2-3 soft stools per day. Maximum 60 mL/day.
Administered as an intraperitoneal infusion for organ preservation. Typical adult dose: 2.5-3.0 liters for kidney, 2.5-3.0 liters for liver, 3.0-4.0 liters for pancreas, single dose prior to procurement.
None Documented
None Documented
Not applicable; lactulose is a non-absorbable disaccharide that exerts a local osmotic effect in the colon without systemic absorption. Systemic half-life is not relevant as it does not enter circulation.
Not applicable; Plegisol is not a systemically active drug. Its cardioplegic effect is immediate upon perfusion into coronary arteries and dissipates upon reperfusion. The solution's components have endogenous half-lives (e.g., potassium: 1-1.5 h in plasma), but this is not clinically relevant for the product.
Primarily fecal (≥90%) as unchanged drug via colonic excretion; renal elimination is negligible (<1%).
Plegisol is an extracellular cardioplegic solution; its components (electrolytes and calcium) are not metabolized. Elimination of infused volume occurs primarily via renal excretion (approx. 95%) as unchanged water and electrolytes; minor biliary/fecal elimination (<5%) accounts for negligible electrolyte loss.
Category C
Category C
Osmotic Laxative
Osmotic Laxative